Literature DB >> 30362350

Mass Transport Analysis of the Enhanced Buffer Capacity of the Bicarbonate-CO2 Buffer in a Phase-Heterogenous System: Physiological and Pharmaceutical Significance.

Jozef Al-Gousous1, Kathy X Sun1, Daniel P McNamara2, Bart Hens1, Niloufar Salehi1, Peter Langguth3, Marival Bermejo4, Gregory E Amidon1, Gordon L Amidon1.   

Abstract

The bicarbonate buffer capacity is usually considered in a phase-homogeneous system, at equilibrium, with no CO2 transfer between the liquid buffer phase and another phase. However, typically, an in vitro bicarbonate buffer-based system is a phase-heterogeneous system, as it entails continuously sparging (bubbling) the dissolution medium with CO2 in a gas mixture, at constant ratio, to maintain a constant partial pressure of CO2 (g) and CO2(aq) molarity at a prescribed value, with CO2 diffusing freely between the gas and the aqueous phases. The human gastrointestinal tract is also a phase-heterogeneous system, with CO2 diffusing across the mucosal membrane into the mesenteric arterial blood, which serves as a sink for CO2 from the intestinal lumen. In this report, a mass transport analysis of the apparent buffer capacity of a phase-heterogeneous bicarbonate-CO2 system is developed. It is shown that, most significantly, a phase-heterogeneous bicarbonate-CO2 system can have a much higher buffer capacity than a phase-homogeneous system such that the buffer capacity is dependent on the bicarbonate concentration. It is double that of a phase-homogeneous system at the pH = p Ka for a monoprotic buffer at the same concentration. This buffer capacity enhancement increases hyperbolically with pH above the p Ka, thus providing a much stronger buffering to keep the pH in the physiologically neutral range. The buffer capacity will be dependent on the bicarbonate molarity (which in vivo will depend on the bicarbonate secretion rate) and not the pH of the luminal fluid. Further, there is no conjugate acid accumulation as a result of bicarbonate neutralization, since the resulting carbonic acid (H2CO3) rapidly dehydrates producing CO2 and H2O. The mass transport analysis developed in this report is further supported by in vitro experimental results. This enhanced bicarbonate buffer capacity in a phase-heterogeneous system is of physiological significance as well as significant for the dissolution and absorption of ionizable drugs.

Entities:  

Keywords:  CO2; acid and base dissolution; bicarbonate; buffer capacity; in vivo gastrointestinal buffering; phase-heterogeneous

Mesh:

Substances:

Year:  2018        PMID: 30362350     DOI: 10.1021/acs.molpharmaceut.8b00783

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  4 in total

1.  Understanding In Vivo Dissolution of Immediate Release (IR) Solid Oral Drug Products Containing Weak Acid BCS Class 2 (BCS Class 2a) Drugs.

Authors:  Min Li; Xinwen Zhang; Di Wu; Om Anand; Hansong Chen; Kimberly Raines; Lawrence Yu
Journal:  AAPS J       Date:  2021-10-26       Impact factor: 4.009

Review 2.  In Vitro Methodologies for Evaluating Colon-Targeted Pharmaceutical Products and Industry Perspectives for Their Applications.

Authors:  Mauricio A García; Felipe Varum; Jozef Al-Gousous; Michael Hofmann; Susanne Page; Peter Langguth
Journal:  Pharmaceutics       Date:  2022-01-26       Impact factor: 6.321

3.  Lost in modelling and simulation?

Authors:  Kiyohiko Sugano
Journal:  ADMET DMPK       Date:  2021-03-22

4.  A Mechanistic Physiologically-Based Biopharmaceutics Modeling (PBBM) Approach to Assess the In Vivo Performance of an Orally Administered Drug Product: From IVIVC to IVIVP.

Authors:  Marival Bermejo; Bart Hens; Joseph Dickens; Deanna Mudie; Paulo Paixão; Yasuhiro Tsume; Kerby Shedden; Gordon L Amidon
Journal:  Pharmaceutics       Date:  2020-01-17       Impact factor: 6.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.